Utility of genetic screening in hypertrophic cardiomyopathy: Prevalence and significance of novel and double (homozygous and heterozygous) β-myosin mutations

Genetic Testing

Volumn 7, Issue 1, 2003, Pages 21-27

  Mohiddin, Saidi A ^a   Begley, David A ^a   McLam, Elisha ^a   Cardoso, John Paul ^a   Winkler, Judith B ^a   Sellers, James R ^a   Fananapazir, Lameh ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Cardiology Branch   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA MYOSIN; GENOMIC DNA; GLUTAMINE; HISTIDINE; LEUCINE; LYSINE; MYOSIN HEAVY CHAIN; PROLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM ENLARGEMENT; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; SARCOMERE; SEQUENCE ANALYSIS; SYNCOPE;

ADOLESCENT; ADULT; BASE SEQUENCE; CARDIOMYOPATHY, HYPERTROPHIC; FEMALE; GENETIC SCREENING; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; PEDIGREE; PHENOTYPE; PREVALENCE; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; VENTRICULAR MYOSINS;

EID: 0037357857     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/109065703321560895     Document Type: Article

References (21)

1. CHANG, A.C., MCAREAVEY, D., and FANANAPAZIR, L. (1995). Identification of patients with hypertrophic cardiomyopathy at high risk for sudden death. Curr. Opin. Cardiol. 10, 9-15.
2. ENJUTO, M., FRANCINO, A., NAVARRO-LOPEZ, F., et al. (2000). Malignant hypertrophic cardiomyopathy caused by the Arg723Gly mutation in beta-myosin heavy chain gene. J. Mol. Cell. Cardiol. 32, 2307-2313.
3. Leu→Val mutation and a 402 Arg → Gln mutation. Circulation 86, 345-352.
4. FANANAPAZIR, L. (1999). Advances in molecular genetics and management of hypertrophic cardiomyopathy. J. Am. Med. Assn. 281, 1746-1752.
5. FANANAPAZIR, L., and EPSTEIN, N.D. (1994). Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 89, 22-32.
6. FHC MUTATION DATABASE. http://www.angis.org.au/Databases/Heart/dbsearch.html
7. GEISTERFER-LOWRANCE, A.A., KASS, S., TANIGAWA, G., et al. (1990). A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62, 999-1006.
8. GRUVER, E.J., FATKIN, D., DODDS, G.A., et al. (1999). Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am. J. Cardiol. 83, 13H-18H.
9. HOUDUSSE, A., SZENT-GYORGYI, A.G., and COHEN, C. (2000). Three conformational states of scallop myosin S1. Proc. Natl. Acad. Sci. USA 97, 11238-11243.
10. JESCHKE, B., UHL, K., WEIST, B., et al. (1998). A high risk phenotype of hypertrophic cardiomyopathy associated with a compound genotype of two mutated beta-myosin heavy chain genes. Hum. Genet. 102, 299-304.
11. KARIBE, A., TOBACMAN, L.S., STRAND, J., et al. (2001). Hypertrophic cardiomyopathy caused by a novel alpha-tropomyosin mutation (V95A) is associated with mild cardiac phenotype, abnormal calcium binding to troponin, abnormal myosin cycling, and poor prognosis. Circulation 103, 65-71.
12. LANKFORD, E.B., EPSTEIN, N.D., FANANAPAZIR, L., et al. (1995). Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J. Clin. Invest. 95, 1409-1414.
13. MOHIDDIN, S., and FANANAPAZIR, L. (2001). Advances in understanding hypertrophic cardiomyopathy. Hosp. Pract. 36, 23-30.
14. NISHI, H., KIMURA, A., HARADA, H., et al. (1994). Possible gene dose effect of a mutant cardiac beta-myosin heavy chain gene on the clinical expression of familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 200, 549-556.
15. PALMITER, K.A., TYSKA, M.J., HAEBERLE, J.R., et al. (2000). R403Q and L908V mutant beta-cardiac myosin from patients with familial hypertrophic cardiomyopathy exhibit enhanced mechanical performance at the single molecule level. J. Muscle Res. Cell. Motil. 21, 609-620.
16. RAYMENT, I., HOLDEN, H.M., SELLERS, J.R., et al. (1995). Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. USA 92, 3864-3868.
17. RICHARD, P., ISNARD, R., CARRIER, L., et al. (1999). Double heterozygosity for mutations in the beta-myosin heavy chain and in the cardiac myosin binding protein C genes in a family with hypertrophic cardiomyopathy. J. Med. Genet. 36, 542-545.
18. RICHARD, P., CHARRON, P., LECLERCQ, C., et al. (2000). Homozygotes for a R869G mutation in the beta-myosin heavy chain gene have a severe form of familial hypertrophic cardiomyopathy. J. Mol. Cell Cardiol. 32, 1575-1583.
19. TOWBIN, J.A. (2000). Molecular genetics of hypertrophic cardiomyopathy. Curr. Cardiol. Rep. 2, 134-140.
20. VARNAVA, A.M., ELLIOTT, P.M., BABOONIAN, C., et al. (2001). Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 104, 1380-1384.
21. WIGLE, E.D., RAKOWSKI, H., KIMBALL, B.P., et al. (1995). Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 92, 1680-1692.